<unk>  can cause fetal harm and is therefore contraindicated in pregnant women. The substance is also contraindicated in pulmonary hypertension in combination with idiopathic interstitial pneumonia (PH-IIP). A clinical trial testing<unk>  for this purpose was prematurely terminated because it increased severe adverse effects and mortality in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia when compared to placebo.
Riociguat
Vericiguat
Sitaxentan
Cangrelor
Clemastine
Darusentan
Nafoxidine
Bosentan